RUINING XU: Open Payments
NPI 1134957749 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$605 in 13 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $682 · 2025 $605
Food & beverage: $605
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 3 | $157 |
| Viatris Specialty LLC | 1 | $122 |
| Gilead Sciences, Inc. | 1 | $109 |
| SANOFI PASTEUR INC. | 2 | $70 |
| Novo Nordisk Inc | 2 | $57 |
| GlaxoSmithKline, LLC. | 1 | $28 |
| Dynavax Technologies Corporation | 1 | $22 |
| Amgen Inc. | 1 | $22 |
| Exact Sciences Corporation | 1 | $17 |
Products named: MOUNJARO, YUPELRI, Vemlidy, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, Ozempic, TRELEGY ELLIPTA, Heplisav-B.
Industry payments across CA — which companies pay providers there.
